NovaBay has a strategic marketing agreement with China Pioneer Pharma (Hong Kong Stock Exchange, Stock Code 01345.HK), a Shanghai-based marketing, promotion, and channel management service provider. Under the exclusive agreement, China Pioneer Pharma has the distribution rights for CelleRx™ in: China, Hong Kong, Macau, Taiwan, Singapore, Malaysia, Indonesia, Myanmar, Philippines, Thailand, Vietnam, Brunei, Cambodia, and Laos. For more information about China Pioneer Pharma, please go to their website: www.pioneer-pharma.com
NovaBay is actively seeking distribution partners for other countries in the world that aren’t listed above. For business development/licensing inquiries,
please click here. |
|
 |